The global psychotropic drugs market is poised for significant growth, with a projected market size of USD 21,269.4 million in 2023, anticipated to rise to USD 28,876.2 million by 2033. This expansion reflects an estimated CAGR of 3.1% during the forecast period.
The increasing prevalence of mental health disorders, alongside a growing awareness of mental well-being, is driving demand for psychotropic medications. These drugs, which include antidepressants, antipsychotics, and mood stabilizers, are crucial in managing various psychiatric conditions, enabling millions of individuals to lead healthier, more fulfilling lives.
In addition to the rising incidence of mental health disorders, advancements in drug formulations and therapeutic approaches are further fueling market growth. Ongoing research and development efforts aimed at enhancing the efficacy and safety profiles of psychotropic medications are also contributing to the market’s positive outlook.
Over the past decade, healthcare sector has been expanding remarkably, following the advent of artificial Intelligence and the Internet of Things integrated medical devices. Advancement in technology has created impressive scope within the medical sector for diagnostics and therapeutics.
Understanding the Impact of Covid-19 on Healthcare Industry
With the pandemic plaguing maximum countries across the globe, healthcare industry is witnessing its fair share of ‘ups and downs’. The COVID-19 has placed an enormous strain on the healthcare sector’s workforce, facilities and infrastructure. Despite the endless pressure, healthcare sector is growing at a moderate pace due to the improvement in infrastructure and advancement in technology, healthcare sector is delivering a healthy performance.
The FMI’s latest report on the Psychotropic Drugs market gives a detailed analysis on the impact of COVID-19 with an incisive coverage on the innovative strategies adopted by the market players to survive the challenges due to pandemic.
Report Highlights:
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint.
Psychotropic Drugs Market: Regional Overview
Among the regional presence, North America is anticipated to be the most lucrative market for psychotropic drugs owing to increasing preference for antidepressants and anti-psychotic drugs among target population in the U.S. North America and Europe cumulatively accounts for the significant revenue share in psychotropic drugs market due to presence of favourable reimbursement for drugs in most of the European countries. Middle East and Africa and Asian countries however are the least lucrative market for psychotropic drugs owing to least access received by target population.
Detailed analysis on the geographical region and country wise insights are offered in the latest Psychotropic Drugs market report with established market players as well as incumbents in the region.
The global Psychotropic Drugs market can be segmented as follows:
- Analgesics
- Anesthetics
- Anti-psychotics (AP)
- Chlorpromazine
- Thioridazine
- Quetiapine
- Risperidone
- Clozapine
- Others
- Antidepressants (AD)
- Tricyclic Antidepressants (TCAs)
- Monoamine Oxidase Inhibitors (MAOIs)
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
- Others
- Mood Stabilizers (MS)
- Anti-Anxiety (AA)
- Antiepileptic drugs (AEDs)
- Hypnotics
- Stimulants
Comprehensive analysis of the regional markets offers exclusive insights on the market performance across geographies along with relevant graphs, figures, and list of tables.
Psychotropic Drugs Market: Key Players
Some of the major psychotropic drug manufacturers present over the globe are Pfizer Inc., Ely Lilly and Company, Forest Laboratories, Mylan N.V., Randox Laboratories Ltd., FUJIFILM Wako Pure Chemical Corporation and others.
With an extensive SWOT analysis, the FMI’s study presents the strengths, weaknesses, growth prospects and challenges of each player. The report also includes important data including the sales strategy, pricing strategy, and marketing strategy adopted by these players in the Psychotropic Drugs market
Key Segments in the Psychotropic Drugs Market:
By Drug Type:
- Chlorpromazine
- Thioridazine
- Quetiapine
- Risperidone
- Clozapine
- Paroxetine
- Fluvoxamine
- Others
By Application:
- Anti-psychotics
- Antidepressants
- Mood Stabilizers (MS)
- Anti-anxiety (AA)
- Antiepileptic drugs (AEDs)
- Hypnotics
- Stimulants
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific excluding China & Japan
- China
- Japan
- Middle East and Africa
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
